The recognition of significant clinical heterogeneity in ALS, despite a common pathological signature of cytoplasmic TARDBP inclusions in nearly all cases, suggests that there may ultimately be a range of biomarker signatures linked to specific phenotypes or progression rates. Here, TARDBP is linked to amyotrophic lateral sclerosis.